Neuroendocrine differentiation

Last updated

Neuroendocrine differentiation is a term primarily used in relation to prostate cancers that display a significant neuroendocrine cell population on histopathological examination. These types of prostate cancer comprise true neuroendocrine cancers, such as small cell carcinoma, carcinoid and carcinoid-like tumors, as well as prostatic adenocarcinoma exhibiting focal neuroendocrine phenotype. [1]

Contents

Normal function

Prostatic neuroendocrine cells, also known as endocrine-paracrine cells, [1] are part of a larger regulatory cell population scattered throughout the whole organism, collectively known as diffuse neuroendocrine system or APUD cells. [1] Neuroendocrine cells are present in all regions of the human prostate, most notably around the ducts, but also in the acinar epithelium and prostatic urothelium; there is a significant inter-individual variability. [1] [2] Two morphologic types have been described: the open type, extending slender apical processes to the ductal or acinar lumen, and the closed type cells, which lack lumenal protrusions but display dendrite-like processes that extend between adjacent epithelial cells. [1] [2]

Neuroendocrine cells in the human prostate contain a diverse array of secretory products: serotonin (which is present in virtually all neuroendocrine prostatic cells), chromogranin A (CgA), synaptophysin and neuron-specific enolase (NSE) (three proteins that are used as markers for neuroendocrine cells) calcitonin and other peptides of the calcitonin family (calcitonin gene-related peptide (CGRP) and katacalcin, which colocalize to the calcitonin-containing cells), bombesin/gastrin-releasing peptide (GRP), thyroid stimulating hormone-like peptide, parathyroid hormone-related protein (PTHrP), alpha-human chorionic gonadotropin (hCG), somatostatin, cholecystokinin, vasoactive intestinal peptide (VIP), neuropeptide Y, vascular endothelial growth factor (VEGF), and adrenomedullin. [1] [2] [3] The physiology of their secretion and its regulation is incompletely understood. Regulatory cues might come through endocrine, paracrine (from neighboring neuroendocrine cells), autocrine or neurocrine routes. The open type cells may in addition receive regulatory signals from luminal molecules [4] The developmental origin of these cells is as yet unknown. They are thought to arise from a different precursor than other epithelial prostatic cells, possibly through a neurogenic lineage of their own, which is therefore distinct from the secretory and basal cells that derive from urogenital sinus. [4]

Role in prostate cancer

The most heavily studied aspect of neuroendocrine differentiation in prostate cancer (but not the only one, as mentioned above) is the focal type, which refers to a conventional prostatic adenocarcinoma that exhibits neuroendocrine foci at histopathological examination. Tumor xenografts of mice subjected to castration have been shown to undergo rapid regression with a dramatic drop in androgen receptor expression in tumor cells and a steep increase in the proportion of apoptotic cells [5] Following castration, the proportion, as well as the density of neuroendocrine tumor cells, rises abruptly, eventually leading to the formation of neuroendocrine cell islets that are spread throughout the tumor and account for the majority of its constituent cells. [5]

The immunohistochemical phenotype of focal neuroendocrine differentiation in prostate cancer has been intensively studied. Chromogranin A, which is the most abundant product of prostatic neuroendocrine cells and neuroendocrine tumor cells, is widely recognized as a reliable marker for neuroendocrine differentiation. [4] Synaptophysin and neuron-specific enolase are also reliable markers. [3] The most frequently encountered products in neuroendocrine tumor cells across prostate cancer samples appear to be calcitonin (in more than one third of cases), neurotensin, serotonin, human chorionic gonadotropin, vasoactive intestinal peptide (VIP) and bombesin/gastrin-releasing peptide. [6] Neuroendocrine tumor cells express cytokeratins that are typically expressed by luminal secretory type cells, but lack basal cell markers such as high molecular weight cytokeratin and p63. [7] They are negative for androgen receptor and prostate-specific antigen (PSA) and are positive for prostate acid phosphatase. [7] [8] Neuroendocrine tumor cells are also negative for the proliferation marker Ki-67; [5] [7] however, adjacent non-neuroendocrine tumor cells appear to display an increased expression of Ki-67. [7] As opposed to their normal neuroendocrine counterparts, tumor neuroendocrine cells express the beta-oxidative enzyme alpha-methylacyl-CoA racemase, which is a recently described marker for prostate cancer. [7]

As opposed to the focal type of neuroendocrine differentiation seen in prostatic adenocarcinoma, small cell carcinoma of the prostate, in turn, exhibit a universal type in that virtually all the constituent tumor cells display neuroendocrine features. [2] Immunohistochemically, prostatic small cell carcinoma are positive for thyroid transcription factor 1 (TTF-1), CD56, chromogranin A, synaptophysin, neuron-specific enolase, calcitonin and bombesin/gastrin-releasing peptide, while lacking, or rarely and weakly expressing, androgen receptor and prostate-specific antigen. [3] [9]

It is commonly believed that prostatic adenocarcinoma exhibiting significant neuroendocrine differentiation is less differentiated, more aggressive and hormone therapy-resistant. [8]

Related Research Articles

<span class="mw-page-title-main">Calcitonin</span> Amino acid peptide hormone secreted by the thyroid gland

Calcitonin is a 32 amino acid peptide hormone secreted by parafollicular cells (also known as C cells) of the thyroid (or endostyle) in humans and other chordates in the ultimopharyngeal body. It acts to reduce blood calcium (Ca2+), opposing the effects of parathyroid hormone (PTH).

Bombesin is a 14-amino acid peptide originally isolated from the skin of the European fire-bellied toad by Vittorio Erspamer et al. and named after its source. It has two known homologs in mammals called neuromedin B and gastrin-releasing peptide. It stimulates gastrin release from G cells. It activates three different G-protein-coupled receptors known as BBR1, -2, and -3. It also activates these receptors in the brain. Together with cholecystokinin, it is the second major source of negative feedback signals that stop eating behaviour.

<span class="mw-page-title-main">Synaptophysin</span> Protein-coding gene in the species Homo sapiens

Synaptophysin, also known as the major synaptic vesicle protein p38, is a protein that in humans is encoded by the SYP gene.

Neuroendocrine cells are cells that receive neuronal input and, as a consequence of this input, release messenger molecules (hormones) into the blood. In this way they bring about an integration between the nervous system and the endocrine system, a process known as neuroendocrine integration. An example of a neuroendocrine cell is a cell of the adrenal medulla, which releases adrenaline to the blood. The adrenal medullary cells are controlled by the sympathetic division of the autonomic nervous system. These cells are modified postganglionic neurons. Autonomic nerve fibers lead directly to them from the central nervous system. The adrenal medullary hormones are kept in vesicles much in the same way neurotransmitters are kept in neuronal vesicles. Hormonal effects can last up to ten times longer than those of neurotransmitters. Sympathetic nerve fiber impulses stimulate the release of adrenal medullary hormones. In this way the sympathetic division of the autonomic nervous system and the medullary secretions function together.

<span class="mw-page-title-main">Gastrin-releasing peptide</span>

Gastrin-releasing peptide, also known as GRP, is a neuropeptide, a regulatory molecule that has been implicated in a number of physiological and pathophysiological processes. Most notably, GRP stimulates the release of gastrin from the G cells of the stomach.

<span class="mw-page-title-main">LNCaP</span>

LNCaP cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells.

<span class="mw-page-title-main">Neuroendocrine tumor</span> Medical condition

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung, and the rest of the body.

<span class="mw-page-title-main">Chromogranin A</span> Mammalian protein found in Homo sapiens

Chromogranin A or parathyroid secretory protein 1 is a member of the granin family of neuroendocrine secretory proteins. As such, it is located in secretory vesicles of neurons and endocrine cells such as islet beta cell secretory granules in the pancreas. In humans, chromogranin A protein is encoded by the CHGA gene.

<span class="mw-page-title-main">Neprilysin</span> Mammalian protein found in Homo sapiens

Neprilysin, also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. It also degrades the amyloid beta peptide whose abnormal folding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been transported from the Golgi apparatus to the cell surface.

Hormonal therapy in oncology is hormone therapy for cancer and is one of the major modalities of medical oncology, others being cytotoxic chemotherapy and targeted therapy (biotherapeutics). It involves the manipulation of the endocrine system through exogenous or external administration of specific hormones, particularly steroid hormones, or drugs which inhibit the production or activity of such hormones. Because steroid hormones are powerful drivers of gene expression in certain cancer cells, changing the levels or activity of certain hormones can cause certain cancers to cease growing, or even undergo cell death. Surgical removal of endocrine organs, such as orchiectomy and oophorectomy can also be employed as a form of hormonal therapy.

<span class="mw-page-title-main">Gastrin-releasing peptide receptor</span> Protein-coding gene in the species Homo sapiens

The gastrin-releasing peptide receptor (GRPR), now properly known as BB2 is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.

<span class="mw-page-title-main">NKX3-1</span> Protein-coding gene in the species Homo sapiens

Homeobox protein Nkx-3.1, also known as NKX3-1, NKX3, BAPX2, NKX3A and NKX3.1 is a protein that in humans is encoded by the NKX3-1 gene located on chromosome 8p. NKX3-1 is a prostatic tumor suppressor gene.

Large cell lung carcinoma with rhabdoid phenotype (LCLC-RP) is a rare histological form of lung cancer, currently classified as a variant of large cell lung carcinoma (LCLC). In order for a LCLC to be subclassified as the rhabdoid phenotype variant, at least 10% of the malignant tumor cells must contain distinctive structures composed of tangled intermediate filaments that displace the cell nucleus outward toward the cell membrane. The whorled eosinophilic inclusions in LCLC-RP cells give it a microscopic resemblance to malignant cells found in rhabdomyosarcoma (RMS), a rare neoplasm arising from transformed skeletal muscle. Despite their microscopic similarities, LCLC-RP is not associated with rhabdomyosarcoma.

Neuroendocrine adenoma middle ear (NAME) is a tumor which arises from a specific anatomic site: middle ear. NAME is a benign glandular neoplasm of middle ear showing histologic and immunohistochemical neuroendocrine and mucin-secreting differentiation.

<span class="mw-page-title-main">Pancreatic tumor</span> Medical condition

A pancreatic tumor is an abnormal growth in the pancreas. In adults, almost 90% are pancreatic cancer and a few are benign. Pancreatic tumors are rare in children.

<span class="mw-page-title-main">Pancreatic neuroendocrine tumor</span> Medical condition

Pancreatic neuroendocrine tumours, often referred to as "islet cell tumours", or "pancreatic endocrine tumours" are neuroendocrine neoplasms that arise from cells of the endocrine (hormonal) and nervous system within the pancreas.

A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring. The most common histopathological subdiagnosis of prostate cancer is acinar adenocarcinoma, constituting 93% of prostate cancers. The most common form of acinar adenocarcinoma, in turn, is "adenocarcinoma, not otherwise specified", also termed conventional, or usual acinar adenocarcinoma.

Pro-Gastrin-Releasing-Peptide, also known as Pro-GRP, is a Gastrin-Releasing-Peptide (GRP) precursor, a neurotransmitter that belongs to the bombesine/neuromedin B family. GRP stimulates the secretion of gastrin in order to increase the acidity of the gastric acid. Pro-GRP is a peptide composed of 125 amino acids, expressed in the nervous system and digestive tract. It is also important to not confused with progastrin, consisting of 80 amino acids, precursor of gastrin in its intracellular version and oncogene in its extracellular version (hPG80).

Progastrin is an 80-amino acid intracellular protein and the precursor of gastrin, a gastrointestinal hormone produced by G cells in the gastric antrum. The main function of gastrin is to regulate acid secretion. During digestion, only gastrin is released into the bloodstream and stimulates the secretion of hydrochloric acid in the stomach as well as pancreatic digestive enzymes. In humans, progastrin is encoded by the GAST gene. Progastrin is expressed primarily in stomach tissue.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

References

  1. 1 2 3 4 5 6 di Sant'Agnese PA (July 1992). "Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications". Cancer. 70 (1 Suppl): 254–68. doi: 10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e . PMID   1350941.
  2. 1 2 3 4 Abrahamsson PA (1996). "Neuroendocrine differentiation and hormone-refractory prostate cancer". The Prostate. Supplement. 6 (S6): 3–8. doi:10.1002/(SICI)1097-0045(1996)6+<3::AID-PROS2>3.0.CO;2-T. PMID   8630226. S2CID   8846395.
  3. 1 2 3 Sun Y, Niu J, Huang J (2009). "Neuroendocrine differentiation in prostate cancer". American Journal of Translational Research. 1 (2): 148–62. PMC   2776313 . PMID   19956427.
  4. 1 2 3 Vashchenko N, Abrahamsson PA (February 2005). "Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities". European Urology. 47 (2): 147–55. doi:10.1016/j.eururo.2004.09.007. PMID   15661408.
  5. 1 2 3 Jongsma J, Oomen MH, Noordzij MA, et al. (February 1999). "Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model". The American Journal of Pathology. 154 (2): 543–51. doi:10.1016/S0002-9440(10)65300-X. PMC   1850014 . PMID   10027412.
  6. ↑ Ishida E, Nakamura M, Shimada K, Tasaki M, Konishi N (2009). "Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer". Pathobiology. 76 (1): 30–8. doi: 10.1159/000178153 . PMID   19188748.
  7. 1 2 3 4 5 Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y (September 2006). "Immunohistochemical characterization of neuroendocrine cells in prostate cancer". The Prostate. 66 (13): 1399–406. doi:10.1002/pros.20434. PMID   16865726. S2CID   43634696.
  8. 1 2 Bonkhoff H (2001). "Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status". Annals of Oncology. 12 Suppl 2: S141–4. doi: 10.1093/annonc/12.suppl_2.s141 . PMID   11762342.
  9. ↑ Yao JL, Madeb R, Bourne P, et al. (June 2006). "Small cell carcinoma of the prostate: an immunohistochemical study". The American Journal of Surgical Pathology. 30 (6): 705–12. doi:10.1097/00000478-200606000-00005. PMID   16723847. S2CID   19086188.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.